Hi,
We are deciding between Illumina's TruSeq and NimbleGen's SeqCap EZ v 3.0 exome kits, and would appreciate any insight to help us make the decision.
We plan to perform exome sequeincing in two contexts:
1. Sequencing tumor-normal pairs for cancer patients.
2. Sequencing individuals with a particular condition to identify variants implicated in it.
There should be RNA Seq hapening as well, on the same individuals.
Can anyone who has experience with either or both of these kits comment on their use for these kinds of applications?
As I understand, the trade-off involved is one between quality/efficiency of sequencing of the exome itself (NimbleGen) and coverage of the UTRs (Illumina). Is the latter a useful thing in clinical applications? Anything else to think/worry about?
P.S. I have read the Snyder paper, although, being new to this field, might have missed something in it.
We are deciding between Illumina's TruSeq and NimbleGen's SeqCap EZ v 3.0 exome kits, and would appreciate any insight to help us make the decision.
We plan to perform exome sequeincing in two contexts:
1. Sequencing tumor-normal pairs for cancer patients.
2. Sequencing individuals with a particular condition to identify variants implicated in it.
There should be RNA Seq hapening as well, on the same individuals.
Can anyone who has experience with either or both of these kits comment on their use for these kinds of applications?
As I understand, the trade-off involved is one between quality/efficiency of sequencing of the exome itself (NimbleGen) and coverage of the UTRs (Illumina). Is the latter a useful thing in clinical applications? Anything else to think/worry about?
P.S. I have read the Snyder paper, although, being new to this field, might have missed something in it.